Group 1: Investment Activity - Ally Bridge Group NY LLC acquired 178,100 shares of Avalo Therapeutics, valued at approximately $2,264,000, making it 1.4% of their portfolio and the 18th largest position [2] - Other institutional investors, including Ameriprise Financial Inc. and Caligan Partners LP, also increased their stakes in Avalo Therapeutics, with investments of $2,714,000 and $10,592,000 respectively [3] - Orbimed Advisors LLC raised its stake by 39.5%, now owning 1,349,300 shares worth $17,150,000, while Two Sigma Investments LP increased its holdings by 282.0% [3] Group 2: Analyst Ratings and Price Targets - Weiss Ratings reaffirmed a "sell (d-)" rating, while HC Wainwright issued a "buy" rating with a target price of $25.00 [4] - Mizuho upgraded Avalo Therapeutics to a "strong-buy" rating, and Guggenheim set a "buy" rating with a $50.00 price target [4] - The average rating for the stock is "Moderate Buy" with a consensus target price of $33.00 [4] Group 3: Company Overview and Performance - Avalo Therapeutics is a clinical-stage biotechnology company focused on therapies for cardiometabolic, fibrotic, and inflammatory diseases [6] - The company’s lead programs include AVTX-002 for hypertension and AVTX-006 targeting fibrosis and metabolic dysfunction [7] - As of the latest data, Avalo Therapeutics has a market capitalization of $292.46 million, with a 1-year low of $3.39 and a high of $20.72 [5]